Literature DB >> 7253967

Isolation of Clostridium difficile from the feces and the antibody in sera of young and elderly adults.

S Nakamura, M Mikawa, S Nakashio, M Takabatake, I Okado, K Yamakawa, T Serikawa, S Okumura, S Nishida.   

Abstract

Attempts were made to isolate Clostridium difficile from a total of 431 fecal specimens from 149 young and 213 elderly healthy adults, and 69 elderly adults with cerebrovascular disease but no gastrointestinal disease. C difficile was isolated from 49 specimens, and the frequency of isolation was 15.4% in healthy young adults, 7.0% in healthy elderly adults, and 15.9% in elderly adults with cerebrovascular disease. Thirty-four (about 70%) of the 49 C. difficile strains isolated produced cytotoxin which was neutralized by Clostridium sordellii antitoxin in vitro; in both young and elderly adults approximately 30% of the C. difficile isolates were nontoxigenic. The mean concentration of C. difficile in feces was 10(4.1)/g in young adults and 10(4.6)/g in elderly adults, with a range of 10(2.0) to 10(6.9)/g. Antibody against C. difficile toxin was found in most of the sera obtained from young adults carrying toxigenic C. difficile, but not in sera of elderly adults, no matter how abundant was toxigenic C. difficile in the feces.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7253967     DOI: 10.1111/j.1348-0421.1981.tb00036.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  31 in total

Review 1.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

2.  Toxin-producing Clostridium difficile strains as long-term gut colonizers in healthy infants.

Authors:  Ingegerd Adlerberth; Haihui Huang; Erika Lindberg; Nils Åberg; Bill Hesselmar; Robert Saalman; Carl Erik Nord; Agnes E Wold; Andrej Weintraub
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

Review 3.  Antibodies for treatment of Clostridium difficile infection.

Authors:  David P Humphreys; Mark H Wilcox
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

4.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

5.  The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Authors:  Justyna Bien; Vindhya Palagani; Przemyslaw Bozko
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

Review 6.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

7.  Serum neutralizing antibody response to the vacuolating cytotoxin of Helicobacter pylori.

Authors:  T L Cover; P Cao; U K Murthy; M S Sipple; M J Blaser
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Binding kinetics of Clostridium difficile toxins A and B to intestinal brush border membranes from infant and adult hamsters.

Authors:  R D Rolfe
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

Review 9.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 10.  Clostridium difficile Infection in Children: Current State and Unanswered Questions.

Authors:  Pranita D Tamma; Thomas J Sandora
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-25       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.